Effects of food, antacid, and dosage form on the pharmacokinetics and relative bioavailability of sertindole in healthy volunteers

Biopharmaceutics and Drug Disposition

Volumn 18, Issue 6, 1997, Pages 533-541

  Wong, Shekman L ^a   Linnen, Paul ^a   Mack, Randall ^a   Richard Granneman, G ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Antacid; Food; Sertindole

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; ANTACID AGENT; SERTINDOLE;

ADULT; ARTICLE; BIOAVAILABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; ALUMINUM HYDROXIDE; ANALYSIS OF VARIANCE; ANTACIDS; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DRUG COMBINATIONS; FASTING; FOOD-DRUG INTERACTIONS; HUMANS; IMIDAZOLES; INDOLES; MAGNESIUM HYDROXIDE; MALE; SOLUTIONS; TABLETS;

EID: 0030852773     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199708)18:6<533::AID-BDD42>3.0.CO;2-J     Document Type: Article

References (9)

1. C. Sanchez, J. Arnt, N. Dragsted, J. Hyttel, H. L. Lembol, E. Meier, J. Perreg and T. Skarsfeldt, Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selectivc neuroleptic compound. Drug Dev. Res., 22, 239-250 (1991).
2. 2 and alpha 1 receptors (ex vivo radioreceptor binding studies). J. Neural Transm. Gen. Sect., 89, 61-69 (1992).
3. T. Skarsfeldt, Pharmacology of sertindole, a novel atypical neuroleptic. In New Veneration of Antipsychotic Drugs: Novel Mechanisms of Action, N. Brunello, J. Mendlewicz and G. Racagni (Eds), Karger, Basel, 1993, pp. 62-66.
4. D. P. VanKammen, J. P. McEvoy, S. D. Targum, D. Kardutzke and T. H. Sebree, A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology. 123, 168-175 (1996).
5. P. T. Martin, J. A. Grebb, P. Schmitz, T. B. Sebree and K. B. Kashkin, Efficacy and safety of scrtindole in two double-blind, placebo-controlled trials of schizophrenic patient. Schizophr. Res., 11, 107 (1994).
6. C. Schulz, J. Staser, P. Schmitz, R. Mack and T. Sebree, An open-label assessment of the long-term safety of sertindole in the treatment of schizophrenic patients. Marcus Wallenberg Symposium tin Schizophrenia, Gothenberg, September 1994.
7. D. E. Casey, S. Targum, D. Zimbroff, R. Mack, J. Zborowski, D. Morris, T. Sebree and B. Wallin, Efficacy, safety, and dose response of three doses of sertindole and three doses of haldol in schizophrenic patients. Abstract. Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 1995.
8. S. L. Wong, T. Sebree, W. M. Awni and G. R. Granneman, Nonlinear pharmacokinetics of sertindole, a new anti-psychotic compound. Pharm. Res.. 12, S391 (1995).
9. T. B. Tzeng, G. Stamm and S. Y. Chu, Sensitive method for the assay of sertindole in plasma by high-performance liquid chromatography and fluorimetric detection. J. Chromatogr., 18, 299-306 (1994).